Private
The Biomedical Advanced Research and Development Authority (BARDA) and Snapdragon Chemistry are teaming up to develop a continuous manufacturing platform to produce a specific raw material for COVID-19 vaccines.
They are developing ribonucleotide triphosphates (NTPs), a critical raw material for... Read More »
Regeneron Pharmaceuticals initiated the first clinical trial of REGN-COV2, an antibody cocktail for the prevention and treatment of COVID-19.
The REGN-COV2 clinical program will consist of four separate study populations, including hospitalized COVID-19 patients, non-hospitalized symptomatic... Read More »
Health experts maintain the federal government needs to craft a plan to distribute COVID-19 vaccines in Black and Latino that have borne the brunt of the pandemic nationwide.
“They are going to have to make sure we have a sound distribution plan to make sure that we don’t repeat the mistakes... Read More »
Testing of Moderna’s mRNA-1273 COVID-19 vaccine candidate moved forward this week, with the announcement that arrangements are being made to study 30,000 subjects as part of a phase 3 study in July and manufacturing set to reach as high as 1 billion 100 microgram doses per year in... Read More »
Emergent BioSolutions Inc. announced Thursday it signed an agreement to provide its contract development and manufacturing (CDMO) services to support AstraZeneca's COVID-19 vaccine candidate in the United States.
The agreement, valued at approximately $87 million, gives Emergent stateside... Read More »
Another SARS-CoV-2 laboratory diagnostic has caught the attention of the Biomedical Advanced Research and Development Authority (BARDA), which is teaming up with OraSure Technology, Inc. to get it United States Food and Drug Administration (FDA) Emergency Use Authorization (EUA).
This test,... Read More »
For three years, the Biomedical Advanced Research and Development Authority (BARDA) has supported the development of Chembio Diagnostics’ DPP Zika IgM System diagnostic system, and now, the result has been approved for marketing by the U.S. Food and Drug Administration.
The test detects... Read More »
The Biomedical Advanced Research and Development Authority (BARDA) and the Defense Advanced Research Projects Agency (DARPA) have reached an interagency agreement with AstraZeneca to support phase 1 clinical development of a monoclonal antibody combination therapy for use against COVID-19.
This... Read More »
The University of Queensland (UQ) has partnered up with CSL and the Coalition for Epidemic Preparedness Innovations (CEPI) to accelerate development, manufacturing, and distribution of a COVID-19 vaccine candidate its researchers pioneered earlier this year.
In an agreement formalized this week,... Read More »
Results are in from the phase 1 human trial of the Bavarian Nordic A/S vaccine candidate MVA-BN WEV, a prophylactic meant for use against three equine encephalitis viruses, and the data paints the picture of a well-tolerated vaccine capable of spurring immune responses.
The vaccine is meant to... Read More »
FLIR Systems officials said the company has developed software for its T-Series, Exx-Series, and A-Series thermal imaging cameras to perform COVID-19 elevated skin temperature screenings in high-traffic areas.
Officials said the process via FLIR Screen-EST can be conducted in two seconds or less... Read More »
RAND Corp. recently developed an analytical tool that can be used to predict the regional risks of importing cases of COVID-19.
The tool can be used by policymakers to mitigate the threat to public health.
The COVID-19 Air Traffic Visualization tool uses International Air Transport... Read More »
A coalition of AbbVie, Harbour BioMed (HBM), Utrecht University (UU), and Erasmus Medical Center (EMC) have joined together to create a monoclonal antibody therapy that could hold the key to preventing and treating COVID-19, through its viral cause: SARS-CoV-2.
The therapeutic is based on a... Read More »
As part of an expansion to their existing partnership, the Biomedical Advanced Research and Development Authority (BARDA) and MODERNATX, Inc. will increase the domestic manufacturing capacity of the mRNA-1273 vaccine, a candidate to stop the spread of COVID-19.
The relationship has been ongoing... Read More »
Bell Textron Inc., has reached agreements with nine aerospace industry firms to form Team Invictus, which will produce the Bell 360 Invictus prototype for the U.S. Army.
“Team Invictus is working together to show how cutting-edge technology will give soldiers the ability to confidently operate... Read More »
The Coalition for Epidemic Preparedness Innovations (CEPI) announced it would bring $383 million to a new partnership with AstraZeneca this week to guarantee 300 million globally accessible doses of the company’s AZD1222 vaccine candidate for COVID-19.
That vaccine still has to be proven safe... Read More »
The Coalition for Epidemic Preparedness Innovations (CEPI) has partnered with Bharat Biotech (BBIL) and the International Vaccine Institute (IVI) to develop a Chikungunya vaccine, providing as much as $14.1 million for manufacturing and clinical development.
On the line is a two-dose,... Read More »
First responders and healthcare workers stand to benefit from a new partnership between the Biomedical Advanced Research and Development Authority (BARDA) and Evidation Health, which are sifting through data from wearable devices to create an early warning algorithm for COVID-19 symptoms.
This... Read More »
Hollingsworth & Vose has secured a $2.2 million Department of Defense (DoD) contract to increase domestic ventilator and respirator production.
The effort involves producing 27.5 million N95 filters, and 3.1 million N95 respirators per monthly, beginning in August. The endeavor is in support of... Read More »
Scientists and engineers at Texas A&M University are developing a device that can rapidly identify antibodies that can neutralize infection by SARS-CoV-2, the virus that causes COVID-19.
"The difficulty of developing therapeutics and vaccines against emerging viral threats can also be obviously... Read More »
The Biomedical Advanced Research and Development Authority (BARDA) is working with Quidel Corp. to develop to detect COVID-19 and three additional respiratory viruses.
The two will work together to develop a rapid multi-analyte diagnostic test for use on the Sofia 2 assay system to detect the... Read More »
The latest addition to the Biomedical Advanced Research and Development Authority’s (BARDA) COVID-19 countermeasure portfolio is an automated total antibody test being developed in partnership with Siemens Healthineers.
The serological, lab-based test proposes to detect two items in human... Read More »
Pentagon officials said FLIR Systems has installed its EST screening system at the Visitor Center in Washington, D.C., to screen visitors for potential COVID-19 symptoms.
“For more than 40 years, FLIR has provided advanced thermal imaging technology to America’s military — on its aircraft,... Read More »
BAE Systems said it has completed the initial test of its APKWS laser-guided rockets from a tactical configuration ground-based weapon system.
“Our customers see the value in low-cost, precision-strike capabilities that reduce the risk of collateral damage, and they want the flexibility to... Read More »
A partnership between the Biomedical Advanced Research and Development Authority (BARDA) and biotechnology company Genentech will yield a phase 2 clinical trial to evaluate two investigational drugs for the treatment of severe COVID-19 cases: anti-ST2 and IL-22-Fc.
The drugs will be tested on... Read More »
Defense Advanced Research Projects Agency (DARPA) officials said a pair of California-based firms have been selected to participate in its Gamma Ray Inspection Technology (GRIT) program to aid medical applications.
Lumitron Technologies and RadiaBeam Technologies have initiated efforts to... Read More »
Chimeron Bio and George Mason University's National Center for Biodefense and Infectious Diseases (NCBID) are teaming up to develop a COVID-19 vaccine.
The vaccine development will be based on Chimeron Bio's ChaESARTM self-amplifying RNA technology. Plus, it will integrate Mason's complimenting... Read More »
Operation Warp Speed, the White House-created program to speed up COVID-19 vaccine candidate development and manufacturing domestically, will benefit from a $628 million expansion of an existing public-private partnership with Emergent BioSolutions Inc., the U.S. Department of Health and Human... Read More »
A phase 3 clinical trial that will utilize a mix of Actemra/RoActemra and remdesivir on hospitalized COVID-19 patients with severe pneumonia is expected to begin in June, as part of a collaboration between Roche and Gilead Sciences, Inc.
That trial, REMDACTA, will be double-blind, randomized,... Read More »
GlaxoSmithKline (GSK) said it will manufacture 1 billion doses of its pandemic vaccine adjuvant system in 2021 to support the development of multiple adjuvanted COVID-19 vaccine candidates.
The pharmaceutical company says its pandemic adjuvant technology could make a significant contribution... Read More »
A new reference panel being offered by the U.S. Food and Drug Administration (FDA) proposes an additional, independent validation step to guarantee the quality of COVID-19 diagnostic tests.
Since COVID-19 reached U.S. shores earlier this year, many tests have arisen to detect its viral cause:... Read More »
Recent findings from a NORC at the University of Chicago study have determined if a COVID-19 vaccine becomes available, 49 percent of respondents said they plan to get vaccinated.
The nationwide poll was conducted May 14-18, 2020, via the AmeriSpeak Panel - the probability-based panel of NORC at... Read More »
Merck announced a series of actions against COVID-19 this week, joining the fight against the global pandemic through two agreements that further potential vaccines against its viral source, SARS-CoV-2, and a research collaboration intended to create a novel antiviral candidate.
“With our... Read More »
A COVID-19 vaccine candidate created by Novavax, Inc. and supported by the Coalition for Epidemic Preparedness Innovations (CEPI) began clinical trials this week, with the enrollment of participants in a Phase 1/2 study.
The vaccine in question is called NVX-CoV2373, a stable, prefusion protein... Read More »
Social media companies need to step up and use the technology they already have to limit extremist groups from spreading misinformation and conspiracy theories online, experts said Wednesday during a U.S. House Homeland Security Committee virtual forum on extremism during the COVID-19 pandemic.... Read More »
